The ASAC study, Scandinavian multicentre, placebo-controlled, randomized trial, initiated by our group, investigating the role of aspirin as adjuvant after surgery for colorectal liver metastases, is still recruiting patients and has now 300 of 800 patients included (www.asac.no). The trial is funded by Research Council of Norway, Norwegian Cancer Society, and KLINBEFORSK.
EXCALIBUR study; single centre, un-blinded, three-armed randomized trial for patients with high load of colorectal liver metastases, treated with 1)liver transplantation 2)liver resection 3)hepatic artery infusion of chemotherapy. The trial is approved by the Ethical committee and Norwegian Medicinal Agency and will to be initiated in 2021 (www.excaliburstudy.com).
Precision Medicine in Early Diagnostics and Therapy of Biliary Tract Cancer; is a collaborative project between several groups, led by Sheraz Yaqub, started December 2020.
TESLA trial: Liver Transplantation for Non-Resectable Intrahepatic Cholangiocarcinoma: a prospective exploratory trial; this is a collaborative study between several groups at OUH-KIT treating patients with cholangiocarcinoma
CAMINO study: Investigate the value of MRI in assessing CRC liver mets compared to CT scan, and if MRI affects the surgical decision.
Del Zompo F, Crouchet E, Ostyn T, Nehme Z, Messé M, Juehling F, Désert R, Vieira AT, Moehlin J, Nakib D, Andrews T, Perciani C, Chung S, Bader G, McGilvray I, Caime C, Scaravaglio M, Carbone M, Invernizzi P, Yaqub S, Folseraas T, Karlsen TH, Shankar G, Primeaux M, Dhawan Pet al.(2025) Claudin-1 is a mediator and therapeutic target in primary sclerosing cholangitis J Hepatol(in press) DOI 10.1016/j.jhep.2025.08.005, PubMed 40846184
Farnes I, Verbeke CS, Kleive D, Waage A, Tholfsen T, Hagen M, Fosby B, Line PD, Labori KJ(2025) Surgical, Histopathological, and Quality of Life Outcomes Following Neoadjuvant Chemotherapy and Pancreatectomy for Borderline Resectable and Locally Advanced Pancreatic Cancer Cancers (Basel), 17(15) DOI 10.3390/cancers17152505, PubMed 40805202
Abbassi F, Pfister M, Braun J, Angenete E, Haglind E, Onerup A, Heijmans MH, Slooter GD, Molenaar CJ, Fiore JF, Feldman LS, Pecorelli N, Guarneri G, Falconi M, Drejian SK, Fretland ÅA, Edwin B, Ubels S, Hannink G, Puhan MA, Clavien PA(2025) Beyond P Values: Novel Minimal Important Difference of the Comprehensive Complication Index (CCI®) that reflects a Meaningful Outcome for Patients Undergoing Major Abdominal Surgery Ann Surg(in press) DOI 10.1097/SLA.0000000000006877, PubMed 40793921